1 week Ago By ABMN Staff
Shares of Ultragenyx Pharmaceutical Inc. ( NASDAQ:RARE – Get Free Report ) have received a consensus rating of “Moderate Buy” from the fourteen analysts that are covering the stock, MarketBeat.com reports.
One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $87.43.
RARE has been the subject of several research reports. Wedbush boosted their price objective on shares of Ultragenyx Pharmaceutical from $43.00 to $46.
00 and gave the company a “neutral” rating in a research note on Friday, August 2nd. Barclays dropped their price target on Ultragenyx Pharmaceutical from $83.00 to $81.
00 and set an “overweight” rating for the company in a research note on Monday, August 5th. The Goldman Sachs Group lifted their price objective on Ultragenyx Pharmaceutical from $67.00 to $76.
00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Bank of America decreased their target price on Ultragenyx Pharmaceutical from $83.00 to $76.
00 and set a “buy” rating for the company in a report on Friday, May 31st. Finally, Robert W. Baird raised their price target on shares of Ultragenyx Pharmaceutical from $68.
00 to $72.00 and gave the company an “outperform” rating in a report on Friday, May 31st. Check Out Our Latest Stock Report on Ultragenyx Pharmaceutical Insider Buying and Selling at Ultragenyx Pharmaceutical Hedge Funds Weigh In On Ultragenyx Pharmaceutical Several large investors have recently added to or reduced their stakes in RARE.
Van ECK Associates Corp raised its stake in Ultragenyx Pharmaceutical by 34.0% during the fourth quarter. Van ECK Associates Corp now owns 1,578 shares of the biopharmaceutical company’s stock worth $75,000 after acquiring an additional 400 shares during the period.
Victory Capital Management Inc. boosted its position in Ultragenyx Pharmaceutical by 44.6% during the 4th quarter.
Victory Capital Management Inc. now owns 10,565 shares of the biopharmaceutical company’s stock valued at $505,000 after purchasing an additional 3,259 shares during the period. Natixis Advisors L.
P. grew its stake in Ultragenyx Pharmaceutical by 10.8% during the 4th quarter.
Natixis Advisors L.P. now owns 15,289 shares of the biopharmaceutical company’s stock worth $731,000 after buying an additional 1,496 shares during the last quarter.
Amalgamated Bank increased its position in Ultragenyx Pharmaceutical by 10.0% in the fourth quarter. Amalgamated Bank now owns 15,716 shares of the biopharmaceutical company’s stock worth $752,000 after buying an additional 1,427 shares during the period.
Finally, M&T Bank Corp bought a new stake in Ultragenyx Pharmaceutical in the fourth quarter valued at $310,000. 97.67% of the stock is currently owned by institutional investors.
Ultragenyx Pharmaceutical Trading Down 2.1 % NASDAQ RARE opened at $55.24 on Friday.
The business’s 50-day moving average price is $48.85 and its 200 day moving average price is $45.99.
Ultragenyx Pharmaceutical has a twelve month low of $31.52 and a twelve month high of $58.73.
The company has a market capitalization of $4.59 billion, a PE ratio of -6.88 and a beta of 0.
56. Ultragenyx Pharmaceutical ( NASDAQ:RARE – Get Free Report ) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.
52) earnings per share for the quarter, topping the consensus estimate of ($1.64) by $0.12.
Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 266.02%.
The business had revenue of $147.03 million for the quarter, compared to analyst estimates of $123.20 million.
During the same period in the prior year, the firm posted ($2.25) EPS. The company’s revenue was up 35.
7% on a year-over-year basis. Equities analysts predict that Ultragenyx Pharmaceutical will post -6.24 EPS for the current year.
About Ultragenyx Pharmaceutical ( Get Free Report Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. Featured Articles Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.
com's FREE daily email newsletter ..
